Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Hyperion Therapeutics Drug Gets FDA Orphan Status

By Pharmaceutical Processing | May 3, 2013

SOUTH SAN FRANCISCO, Calif. (AP) — Hyperion Therapeutics Inc. said Thursday that its drug Ravicti received orphan drug status, giving the drug seven years of marketing exclusivity.

Ravicti was approved Feb. 1 as a treatment for urea cycle disorders, a rare type of enzyme deficiency, in patients 2 years and older. The Food and Drug Administration’s decision to grant orphan drug status will keep similar products off the market until Feb. 1, 2020.

Urea cycle disorders are genetic conditions caused by deficiency in an enzyme that removes ammonia from the bloodstream. That deficiency causes ammonia to build up in the patient’s bloodstream.

Separately, Hyperion said it exercised options to acquire the rights to two other urea cycle disorder treatments from Valeant Pharmaceuticals Inc. The company said the drug Buphenyl is used to treat the disorders themselves, while Ammonul is used to treat hospitalized patients whose ammonia levels have become dangerously high.

Hyperion said Valeant has 20 days to notify it if it wants to retain Ammonul. If Valeant decides to keep the drug, it will pay Hyperion $13 million. If Valeant decides not to retain the drug, Hyperion will pay Valeant $22 million. Hyperion said it expects the deals to close by May 29.

Shares of Hyperion rose $1.76, or 8.8 percent, to $21.76 in afternoon trading. They have traded in a 52-week range of $9.95 to $26.50.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE